But wait..... don't give up yet.
BLIS K12 Gains Australian Regulatory Approval
Blis Technologies has received notification from the Australian Therapeutic
Goods Administration, that its probiotic strain Streptococcus salivarius BLIS
K12 has been approved as an active ingredient for Listed Complementary
Medicines.
CEO Brian Watson said, "This approval will allow us to enter the Australian
market with our finished product portfolio based on BLIS K12. The Australian
probiotic supplement market is the 6th largest globally and it is growing at
46% annually so represents a priority growth market for Blis. Within the NZ
market, Blis branded BLIS K12 Throat Lozenges are now ranked as the 2nd
largest brand in 'NZ Pharmacy Throat Lozenge' category and the fastest
growing of the top 5 brands. This gives us a lot of confidence in the market
potential of the larger Australian market and we are accelerating our plans
to launch in 2018 based on this important milestone."